/

Workspace

Research & Review

Writing & Publishing

Data & Analysis

Utilities

Account

User Settings

J

Judy C. Boughey

Mayo Clinic in Arizona(US)

Claim or correct this author profile

Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.

827

Papers

23.7K

Citations

80

h-index

325

i10-index

Judy C. Boughey is an academic researcher from Mayo Clinic in Arizona. The author has contributed to research in topics: Breast Cancer Treatment Studies & Breast Lesions and Carcinomas & Breast Implant and Reconstruction. The author has an h-index of 80, co-authored 703 publications.

ORCID: 0000-0003-3820-3228

Research Topics

Breast Cancer Treatment Studies Breast Lesions and Carcinomas Breast Implant and Reconstruction Cancer Genomics and Diagnostics HER2/EGFR in Cancer Research

Papers by this author

works

Adaptive Randomization of Neratinib in Early Breast Cancer

2016 · New England Journal of Medicine · 456 citations

https://doi.org/10.1056/nejmoa1513750

John W. Park Minetta C. Liu Douglas Yee Christina Yau

Identification and Resection of Clipped Node Decreases the False-negative Rate of Sentinel Lymph Node Surgery in Patients Presenting With Node-positive Breast Cancer (T0–T4, N1–N2) Who Receive Neoadjuvant Chemotherapy

2015 · Annals of Surgery · 441 citations

https://doi.org/10.1097/sla.0000000000001375

Judy C. Boughey Karla V. Ballman Huong T. Le‐Petross Linda McCall

Tumor Biology Correlates With Rates of Breast-Conserving Surgery and Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer

2014 · Annals of Surgery · 424 citations

https://doi.org/10.1097/sla.0000000000000924

Judy C. Boughey Linda McCall Karla V. Ballman Elizabeth A. Mittendorf

Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial

2021 · Cancer Cell · 308 citations

https://doi.org/10.1016/j.ccell.2021.05.009

Lajos Pusztai Christina Yau Denise M. Wolf Hyo S. Han

Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial

2013 · The Lancet Oncology · 171 citations

https://doi.org/10.1016/s1470-2045(13)70502-3

Aman U. Buzdar Vera J. Suman Funda Meric‐Bernstam A. Marilyn Leitch

Eliminating breast surgery for invasive breast cancer in exceptional responders to neoadjuvant systemic therapy: a multicentre, single-arm, phase 2 trial

2022 · The Lancet Oncology · 150 citations

https://doi.org/10.1016/s1470-2045(22)00613-1

Henry M. Kuerer Benjamin D. Smith Savitri Krishnamurthy Wei Yang

Research topics

topics

Breast Cancer Treatment Studies

Breast Lesions and Carcinomas

Breast Implant and Reconstruction

Cancer Genomics and Diagnostics

HER2/EGFR in Cancer Research

Chat about Author

Papers

Chat

Click to start Chat